Article Text

Download PDFPDF
Bitter taste of the tobacco industry interference in Brazil
  1. André Salem Szklo1,
  2. Adriana Carvalho2,
  3. Mariana Coutinho Marques de Pinho2,
  4. Mirian Carvalho de Souza3,
  5. Neilane Bertoni1,
  6. Andre Luiz Oliveira da Silva4
  1. 1Tobacco Control Unit (DITAB/CONPREV), Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
  2. 2ACT Health Promotion, Rio de Janeiro, Brazil
  3. 3Population Research Unit, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
  4. 4Brazilian Health Regulatory Agency (ANVISA), Rio de Janeiro, Brazil
  1. Correspondence to Mr André Salem Szklo, Tobacco Control Unit (DITAB/CONPREV), Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil; andreszk{at}hotmail.com

Abstract

Objective Although Brazil became the first country worldwide to ban the sale of all tobacco products with any additive that could alter their flavours and tastes in 2012, its implementation was effectively halted by tobacco industry lawsuits, including a constitutional challenge filed in the Federal Supreme Court in 2013. This study aimed at examining, for the first time in the country, the evolution over time of the new registrations of tobacco products with additives that would have been banned if not for the tobacco industry’s interference (’counterfactual scenario’).

Methods We used the newly available public database on the registration of tobacco products developed by the Health Regulatory Agency (from 2008 onwards). All types of tobacco products intended for the domestic market that contained ‘banned additives in a counterfactual scenario’ and were registered between January 1 and December 31 of each year were selected.

Results Between 2012 and 2023, a total of 1112 new registrations of tobacco products with ‘banned additives’ were recorded. The spread of hookah tobacco registrations started in 2014, and by 2023, the cumulative incidence of registrations containing ‘banned additives’ was 641. Both manufactured cigarettes and hookah products reached their peaks in new registrations in 2020.

Conclusions After 12 years since the resolution intended to ban all additives that change the aroma and taste of tobacco products in Brazil, primarily to prevent smoking initiation, the tobacco industry’s interference continues to successfully block its implementation. Countries facing similar challenges in tobacco control could consider generating comparable national data that might help expose the adverse impacts of tobacco industry interference on public health.

  • Surveillance and monitoring
  • Tobacco industry
  • Public policy
  • Prevention
  • Litigation

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors ASS participated in the data processing, data analysis and as lead author in the elaboration/preparation of the article. AC, MP, MS, NR, and AS participated in the consultancy for data analysis and elaboration/preparation of the article as coauthors.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests No, there are no competing interests.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.